viewAnteris Technologies Ltd

Admedus to change supplier, aims to be more price competitive

A strategic review recently identified the need to be more price competitive.

drip in a patient's arm
Go Medical supplied smaller intravenous consumable medical products

Admedus Ltd (ASX:AHZ) and supplier Go Medical Industries Pty Ltd have concluded their relationship.

Go Medical is a manufacturer of medical devices and accessories for the company’s Infusion business.

Admedus’s CEO Wayne Paterson said: “The company believes that this outcome is in the best interest of all stakeholders in the short, medium, and long-term.

READ: Admedus raises $2.76 million from share purchase plan

“While this may have a short-term impact on the timing of breakeven earnings, the company still aims to be profitable for 2019.

“We have a great team in place who consistently deliver above-target sales revenue and offer premium service to our valued customers.”

Adequate supply to meet near-term demand

Admedus is committed to working closely with existing customers and Go Medical as it transitions the business, and confirms it has adequate supply to meet demand during the 45-day completion period.

This change in the supplier arrangement is expected to have a 5.7% impact on top-line revenue for the financial year.

It is important to note that this change relates only to the supply of smaller intravenous consumable medical products, and has no impact on Admedus’ distribution of infusion pumps to major hospitals.

Admedus making changes to be more competitive

Under the leadership of its new business unit head, Glenn Gilchrist, Admedus has been refreshing its long-term strategic plan for the Infusion business.

This includes assessing its capabilities, organisational footprint, and product portfolio.

The review identified certain products and pricing within the portfolio which needed to be more competitive.

Admedus engaged Go Medical on these topics, seeking a mutually beneficial outcome, but unfortunately were unable to reach agreement.

Quick facts: Anteris Technologies Ltd

Price: 3.9 AUD

Market: ASX
Market Cap: $23.05 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Anteris Technologies Ltd named herein, including the promotion by the Company of Anteris Technologies Ltd in any Content on the Site, the...


Anteris Technologies CEO hails 'very good results' from DurAVR™ human study

Anteris Technologies Ltd's (ASX:AVR) Wayne Paterson caught up with Proactive's Andrew Scott soon after reporting that early results from its first-in-human study of its proprietary DurAVR™ aortic valve found that patient outcomes exceeded the results of what is normally expected following a...

on 19/10/20

2 min read